Argus
•
Aug 12, 2026
HAE: Raising target price to $92.00
Summary
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
TFX: Raising target price to $148.00
Sep 02, 2026
•
TFX
STE: Lowering target price to $253.00
Sep 02, 2026
•
STE
ICUI: Lowering target price to $179.00
Sep 02, 2026
•
ICUI
MMSI: What does Argus have to say about MMSI?
Sep 02, 2026
•
MMSI
PEN: Lowering target price to $355.00
Sep 02, 2026
•
PEN
